The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Janssen; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Janssen (Inst); Macrogenics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus
Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.
 
Hamid Emamekhoo
Consulting or Advisory Role - Bayer; Exelixis
 
Mark Olsen
No Relationships to Disclose
 
Bradley Curtis Carthon
Consulting or Advisory Role - Astellas Medivation; Blue Earth Diagnostics; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Kyn therapeutics (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Kyn therapeutics; RADMETRIX
Research Funding - Kite/Gilead
Patents, Royalties, Other Intellectual Property - My significant other has 5 patents with UCLA. (I)
Travel, Accommodations, Expenses - Lilly
 
Ivor John Percent
No Relationships to Disclose
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Novartis
 
Daniel C. Cho
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Genentech; HUYA Bioscience International; Nektar; Pfizer; Prometheus; PureTech
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Rgenix (Inst); Sanofi (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Lucio N. Gordan
Employment - Florida Medical Clinic
Leadership - Florida Cancer Specialists
Honoraria - Ameris Pharma
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Myriad Genetics
 
Arash Rezazadeh Kalebasty
No Relationships to Disclose
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Richard J. Lee
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Tina C. Young
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jennifer Johansen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending (Inst)